LVM Capital Management Ltd. MI Boosts Stake in Eli Lilly and Company (NYSE:LLY)

LVM Capital Management Ltd. MI increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 31.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,562 shares of the company's stock after acquiring an additional 11,534 shares during the period. Eli Lilly and Company comprises approximately 4.0% of LVM Capital Management Ltd. MI's portfolio, making the stock its 4th biggest holding. LVM Capital Management Ltd. MI's holdings in Eli Lilly and Company were worth $37,490,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. International Assets Investment Management LLC boosted its holdings in shares of Eli Lilly and Company by 87,091.7% during the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock worth $11,041,631,000 after buying an additional 12,448,888 shares during the period. Pathway Financial Advisers LLC lifted its position in Eli Lilly and Company by 92,759.9% during the 3rd quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company's stock worth $905,774,000 after acquiring an additional 1,021,287 shares during the last quarter. Wulff Hansen & CO. boosted its holdings in Eli Lilly and Company by 90,438.0% during the second quarter. Wulff Hansen & CO. now owns 937,068 shares of the company's stock valued at $848,403,000 after acquiring an additional 936,033 shares during the period. Integrated Investment Consultants LLC boosted its holdings in Eli Lilly and Company by 37,140.7% during the third quarter. Integrated Investment Consultants LLC now owns 694,167 shares of the company's stock valued at $614,990,000 after acquiring an additional 692,303 shares during the period. Finally, Comerica Bank increased its stake in shares of Eli Lilly and Company by 71.6% in the second quarter. Comerica Bank now owns 1,512,983 shares of the company's stock worth $1,369,825,000 after purchasing an additional 631,312 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Friday, September 13th. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating for the company in a research report on Monday, November 4th. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, January 1st. Cantor Fitzgerald reissued an "overweight" rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Finally, Truist Financial raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a "buy" rating in a research report on Thursday, October 10th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,002.22.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company's stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

Shares of LLY traded up $12.17 during trading hours on Friday, hitting $799.39. The stock had a trading volume of 3,970,839 shares, compared to its average volume of 3,126,156. The stock has a market capitalization of $758.87 billion, a price-to-earnings ratio of 86.42, a P/E/G ratio of 2.99 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company's fifty day moving average is $786.08 and its two-hundred day moving average is $860.02. Eli Lilly and Company has a 52 week low of $612.70 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business's quarterly revenue was up 20.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 EPS. On average, analysts anticipate that Eli Lilly and Company will post 13.18 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.75%. Eli Lilly and Company's dividend payout ratio (DPR) is 64.86%.

Eli Lilly and Company announced that its board has authorized a share repurchase program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.